Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid effects on BMD in postmenopausal osteoporosis
NCT00909961Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2009
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of zoledronic acid in postmenopausal osteoporosis, sponsored by Novartis. Primary endpoint: Bone Mineral Density at 1 year. Started Nov 2009; status: completed.
02
Drugs
zoledronic acid
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT00909961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00909961.